Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMT2F4
|
|||
| Drug Name |
Litifilimab
|
|||
| Synonyms |
BIIB059
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Cutaneous lupus erythematosus [ICD-11: EB5Z; ICD-10: L80-L99, L93; ICD-9: 710] | Phase 3 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 3 | [2] | ||
| Company |
Biogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-type lectin domain family 4 member C (CLEC4C) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05531565) A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05352919) A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health. | |||
| REF 3 | Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med. 2022 Jul 28;387(4):321-331. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.